GlassScriptPhysician profile
Farhan Abdul Quader
NPI 1215342993
$4,882.44
in general payments reported to CMS, 2019-2025
14 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2021: $66.03 · 2022: $513 · 2023: $1,195 · 2024: $1,201 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,310 · Travel and Lodging: $1,028 · Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,310.00 |
| Travel and Lodging | $1,027.60 |
| Food and Beverage | $485.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,338.31 | 2023-2025 | |
| Olympus Corporation of The Americas | $839.07 | 2024 | Disposable Distal Attachment, Single Use Electrosurgical Knife Kd-655, Olympus |
| Boston Scientific Corporation | $366.96 | 2019-2022 | |
| Apollo Endosurgery US INC | $298.34 | 2022 | |
| Conmed Corporation | $270.06 | 2024-2025 | Conmed Biliary, Conmed Eus, Conmed Polypectomy |
| Ovesco Endoscopy USA, INC. | $246.22 | 2024 | |
| Covidien LP | $232.33 | 2019 | |
| Cook Medical LLC | $150.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.43 | 2023 | Entyvio |
| Olympus America INC. | $29.21 | 2025 | Evis Exera III Colonovideoscope |
| Erbe USA INC | $28.00 | 2023 | Erbe Vio, Erbe |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.50 | 2023 | Plenvu, Xifaxan |
| Lilly USA, LLC | $15.63 | 2024 | Omvoh |
| Abbvie INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhan Quader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.